Gene fusions between androgen-regulated genes and ERG (e.g., TMPRSS2-ERG) occur in ~50% of prostate cancers, with the alteration resulting in the presence of ERG overexpression in both early and late-stage prostate cancer (248, 249). This evidence concerns the gene TMPRSS2 and prostate cancer.